 Good morning. So first, I'd like to mention our support for this from the Marshfield Clinic Research Foundation grant from Delta Dental of Wisconsin, the CTSA from University of Wisconsin and Marshfield Clinic called ICTER, and NHGRI, especially Ian Marpore, who helped us organize a budding consortium to study the oral microbiome and its relationship to systemic health. So our goal is to establish an oral systemic health cohort that across multiple institutions. And in doing so, we wanted to standardize enrollment of patients with electronic health records, electronic dental records, and a set of standard clinical tests, standard microbiome characterization and also have genomic DNA, plasma, and serum. And this is to advance translational medicine and dental care as well. So among the participants in this group, they're listed here and many of these contributed to the standards that we have for enrolling these cohorts. So spoiler alert here that the mouth is part of the body and the microbiome needs to be factored in for risk assessment of some of the most common and costly diseases. And therefore, the microbiome has to be part of personalized medicine. And in order to facilitate this, we would like to gather a set of patients with standardized recruitment and sample collection, et cetera, to advance this field. So where we are at this point is we've been talking about genetics, not so much about the environment, trying to understand better complex diseases here. But one of the large environmental factors is the microbiome, and in particular, the oral microbiome. And that is also influenced by our diet and other environmental factors. But the genetics and the environment, then, of course, contribute to complex diseases, and in particular, to type 2 diabetes, rheumatoid arthritis, and coronary artery disease. So better understanding of this relationship will lead to enhanced predictive medicine and also can address health disparities. Because if we think that medical care, there are disparities in medical care, there are even more significant disparities in dental care. So the NIH, of course, has been fundamental in promoting research in the human microbiome at various sites. And there are also a number of research opportunities and RFA is out on microbiome. If we consider the oral microbiome and look at sort of a healthy tooth here and periodontitis over here, there are very large differences in the bacteria that are in the periodontal space in these two situations. In this case, the deeper pockets, you have anaerobic bacteria, and you have different species, some of which have been shown to contribute to systemic disease. And there's been many advances in understanding the species range of the oral microbiome and other omics that have to do with the microbiome. So in our cohort here, in our group of interested institutions, we've had some progress. We've had a series of conference calls to plan this initiative. We're organizing then this oral systemic health consortium with these standardized recruitment criteria. We've completed a phase one pilot project at Marshfield, and we've standardized all of these things here. In the pilot project, we've enrolled 41 patients so far. We've published a manuscript outlining the project. We have planned enrollment of an additional 2,000 subjects at the Marshfield Clinic. And Inga Peter at Mount Sinai is about to enroll the first of 400 subjects, and again, all coordinated to be standardized so that we can combine any data that comes out of this. And that includes long-term electronic medical records, electronic dental records, host DNA, oral microbiome DNA, and other omics from the oral microbiome, plasma and serum samples, and a series of standardized clinical tests at enrollment. We've, together with all of our colleagues, we've come up with inclusion-exclusion criteria, case definitions, and all of these other details shown here. And this is the review that we've published. And at the Marshfield Clinic, although the clinic has, for 90 years, been focused on the medical health of the population of Wisconsin, we noticed that there were large numbers of our patients that were not receiving dental care. So over the past few years, we've opened up a series of dental clinics for this underserved population. And we have a total of eight right now with a ninth clinic at Black River Falls on the Ho Chiang Indian Reservation. And this is the population that we serve. Of the 41 individuals in the pilot project, we've measured things like cholesterol, fasting, blood glucose, microalbumin, blood pressure, HSCRP, hemoglobin A1C, et cetera. And of the 41 individuals, 35 of them had an aberrant value for one of these tests. And in fact, at least one individual had five aberrant values here. So if we look at the age and type 2 diabetes distribution just of these pilot subjects, these are individuals who have already been diagnosed with type 2 diabetes. But if we look at fasting glucose and type 2 diabetes in this population, we see in orange here are the diabetics, some of which are controlled and some of which are not controlled very well. But we see there are significant numbers of these individuals that have a higher than normal level fasting glucose. If we look at hemoglobin A1C distribution, we also see some individuals here who are on their way to type 2 diabetes. And we also have a large number of these folks that have higher than normal of the high sensitivity C-reactive protein, indicating that there's some inflammatory process going on. So I think what this shows us is that, and this is actually a population that receives relatively good medical care at this time. And these individuals were recruited from the dental clinic at Marshfield and at Chippewa Falls. But in some of the more remote clinics, in particular at Black River Falls, there are some individuals who have never seen a dentist in their whole life. So we think that this will greatly, by providing dental care, it'll greatly improve the lives of these individuals. But also it provides a great opportunity for research in terms of better understanding controlling the microbiome in these individuals could lead to better health. And in addition, again, these very expensive and complex human disorders for which we have some genetic predictors, I think we should be able to enhance that predictability by understanding better the microbiome. So I just wanted to acknowledge the whole team at Marshfield and also my collaborators in this burgeoning network. So thank you. I'll stop here. Thank you, Murray. Any questions for Murray about the project? And perfectly clear. And I'm sure that if any of you are interested in exploring in more detail, you can contact Murray. And I'm sure that as with all of the work groups here, we're always interested in attracting other people that might be interested in participating. So but we are gratified to see that two of our members have actually gotten to the point of enrolling patients in a specific project and have a paper. And I think that's a great outcome. So thank you, Murray. Next, we'll have Karasang present an update on the cancer working group.